These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19882365)

  • 1. Treatment of multiple sclerosis: role of natalizumab.
    Comi G
    Neurol Sci; 2009 Oct; 30 Suppl 2():S155-8. PubMed ID: 19882365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of children with multiple sclerosis.
    Yeh EA
    Paediatr Drugs; 2012 Jun; 14(3):165-77. PubMed ID: 22497553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
    Pittock SJ; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
    Fox RJ; Bethoux F; Goldman MD; Cohen JA
    Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
    Chofflon M
    BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
    Klawiter EC; Cross AH; Naismith RT
    Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and emerging treatment options for multiple sclerosis.
    Polman CH; Uitdehaag BM
    Lancet Neurol; 2003 Sep; 2(9):563-6. PubMed ID: 12941579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational research in neurology and neuroscience 2010: multiple sclerosis.
    Stüve O; Kieseier BC; Hemmer B; Hartung HP; Awad A; Frohman EM; Greenberg BM; Racke MK; Zamvil SS; Phillips JT; Gold R; Chan A; Zettl U; Milo R; Marder E; Khan O; Eagar TN
    Arch Neurol; 2010 Nov; 67(11):1307-15. PubMed ID: 20625066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological treatment of multiple sclerosis].
    Myhr KM
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in multiple sclerosis therapeutics.
    Spain RI; Cameron MH; Bourdette D
    BMC Med; 2009 Dec; 7():74. PubMed ID: 19968863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: therapeutic update.
    Tselis AC; Lisak RP
    Arch Neurol; 1999 Mar; 56(3):277-80. PubMed ID: 10190816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.